Patent Grant
10570417
This application contains a sequence listing, which is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “688097-376US Sequence Listing” and a creation date of Sep. 19, 2017, and having a size of 6 kb. The sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.
The invention relates to the field of medicine and to the field of gene delivery for applications in vaccination and gene therapy. More in particular, the invention relates to recombinant adenovirus and recombinant adenovirus vectors with bidirectional promoters for the expression of two transgenes.
Recombinant human and animal adenoviruses are used extensively for their application in gene therapy and vaccination. For these applications, adenovirus vectors are used as carriers for a gene or genes of interest to be introduced into host cells. For example, adenovirus vectors can be used to express a gene or part thereof encoding a desired antigen to elicit an immune response.
First generation adenovirus vectors typically only included one transgene. Many strategies are published for these first generation vectors. The published strategies report the use of a variety of different adenovirus vectors and show that the transgene expression cassette can been placed in different regions of the adenovirus, for example in the E1 region, the E3 region, or between E4 and the right ITR.
For vaccine purposes, however, more than one antigen or the same antigen from several different strains is often required to achieve protection and broad coverage. Therefore, in certain cases, it is desirable to express at least two antigens from one adenoviral vector. Different approaches to encode two antigens in one adenoviral vector have been described.
In a first two antigen approach, one antigen expression cassette was placed in the E1 region and a second one was placed in the E3 region (e.g. (Vogels et al., 2007)). In a different two antigen approach, one antigen expression cassette was placed in E1 and a second one between E4 and the right ITR (e.g. (Holman et al., 2007; Pham et al., 2009; Schepp-Berglind et al., 2007)). In yet another two antigen approach, the two antigen expression cassettes were placed in the E1 region in a head-to-tail fashion using two different promoter sequences in an attempt to prevent genetic instability by recombination (e.g. (Belousova et al., 2006; Harro et al., 2009)).
Various other two antigen approaches have also been published for different viral vectors, for example with lentiviral vectors. Examples include use of bidirectional promoters or use of an internal ribosomal entry site (IRES) of positive-stranded RNA-viruses (e.g. derived from EMCV) to produce a single transcript that is translated into two proteins (e.g. (Amendola, Venneri, Biffi, Vigna, & Naldini, 2005; Na & Fan, 2010)). Other examples include utilizing the host cell splicing machinery or use of “cleavage” peptides derived from positive-stranded RNA viruses such as the foot-and-mouth-disease 2A sequence or equivalents from other viruses to produce a polyprotein that is cleaved into two proteins. According to published reports, all of these strategies can be equally useful and successful.
When two antigens are encoded in one adenoviral vector, several features of a monovalent vector should be maintained in order to make the multivalent vector both produceable and useful for vaccine purposes. Important features include genetic stability during upscaling, productivity of the vector at large scale, high level expression of both antigens, and immunogenicity of both antigens. However, for most of the published strategies the genetic stability and other features of the vectors have not been systematically analyzed.
Described herein are experimental results showing that approaches described in the prior art for expressing two antigens with a single recombinant adenovirus, lead to: a) reduced genetic stability in the upscaling process of the recombinant adenovirus (as can be mimicked by serial passaging in the helper cell line); b) reduced productivity of the recombinant adenovirus (decreasing the possibility to upscale the vectors to large purified batches); c) reduced expression of the antigens; and/or d) reduced immunogenicity of one or more of the antigens (in mouse model). These are clear disadvantages that do not support large scale use of recombinant adenovirus for expressing two antigens as described in the prior art.
Therefore, a need remains to provide a recombinant adenovirus that is genetically stable and that expresses two antigens in a manner in which the immunogenicity of both antigens is maintained.
The present invention provides methods of making and using recombinant adenovirus (rAd) and rAd vectors. The rAd and rAd vectors comprise two transgenes, wherein a first transgene is operably linked to a bidirectional mouse Cytomegalovirus (mCMV) promoter in one direction and a second transgene is operably linked to the bidirectional mCMV promoter in the other direction. The rAd of the present invention are genetically stable, with no deletion bands detected by PCR analysis up to passage 13 (p13), thus providing genetic stability that is comparable to rAd with only a single transgene. Furthermore, both transgenes are potently expressed based on FACS analysis of transgene expression and ELISPOT and ELISA analysis of the immunogenicity of the expressed antigens with regard to T-cell and B-cell responses. Thus, the rAd of the present invention with a bidirectional promoter were determined to be suitable for use in gene therapy and vaccine applications.
The general and preferred embodiments are defined, respectively, by the independent and dependent claims appended hereto, which for the sake of brevity are incorporated by reference herein. Other preferred embodiments, features, and advantages of the various aspects of the invention will become apparent from the detailed description below taken in conjunction with the appended drawing figures.
In one embodiment, the present invention provides a recombinant adenovirus comprising a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction.
In another embodiment, the present invention also provides a method of producing a recombinant adenovirus comprising a first and a second transgene, the method comprising: preparing a construct comprising a bidirectional mCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction, and incorporating said construct into the genome of the recombinant adenovirus.
In certain embodiments, the recombinant adenovirus further comprises an intron positioned 3′ of the promoter and 5′ of the first transgene and an intron positioned 3′ of the promoter and 5′ of the second transgene.
In certain embodiments, the recombinant adenovirus has a deletion in the E1 region, and in certain embodiments comprises the bidirectional mCMV promoter and first and second transgenes and optionally the introns, in this E1 region.
In certain embodiments, the first and second transgene are different and at least one of them encodes an antigen. In certain embodiments both encode a different antigen.
In certain embodiments, the adenovirus is a human adenovirus serotype 35 or a human adenovirus serotype 26.
In another embodiment, the present invention also provides a method for expressing at least two transgenes in a cell, the method comprising providing a cell with a recombinant adenoviral vector according to the invention.
In another embodiment, the present invention also provides a method for inducing an immune response against at least two antigens, the method comprising administering to a subject a recombinant adenoviral vector according to the invention.
In another embodiment, the present invention also provides a recombinant DNA molecule comprising the genome of a recombinant adenovirus according to the invention.
In another embodiment, the present invention also provides a pharmaceutical composition comprising a recombinant adenovirus according to the invention and a pharmaceutically acceptable carrier or excipient. In certain embodiments, the pharmaceutical composition is a vaccine.
Described herein are experimental results showing that approaches described in the prior art for expressing two transgenes from one recombinant adenovirus (rAd) lead to genetic instability of the rAd and/or reduced transgene expression compared to rAd with single transgenes expressing the same antigens. After testing several different new strategies to solve these problems, a novel solution was identified using rAd vectors with two transgenes placed under control of a bidirectional mouse Cytomegalovirus (mCMV) promoter. The rAd of the present invention are superior to the bivalent rAd that have been described in the prior art. The bivalent rAd with a bidirectional mCMV are genetically stable, with no deletion bands detected by PCR analysis up to passage 13 (p13), thus providing genetic stability that is comparable to rAd with only a single transgene. Furthermore, both transgenes are potently expressed based on Western Blot and FACS analysis of transgene expression and ELISPOT and ELISA analysis of the immunogenicity of the expressed antigens with regard to T-cell and B-cell responses. Thus, the rAd of the present invention with a bidirectional promoter were determined to be suitable for use in gene therapy and vaccine applications.
The present invention therefore relates to the rAd and the rAd vectors, methods of making and using the rAd and rAd vectors, wherein the rAd and rAd vectors comprise a bidirectional mCMV promoter and two transgenes, wherein a first transgene is operably linked to the bidirectional mCMV promoter in one direction and a second transgene is operably linked to the bidirectional mCMV promoter in the other direction.
The rAd of the present invention can be produced in large amounts, or batches. A ‘batch’ of rAd is a composition that has been produced in one production run in a single production vessel, or alternatively it can refer to the plurality of rAd particles in a composition that is present in a single container (e.g., bioreactor, bag, flask, bottle, multi-dose vial, single-dose vial, syringe, etc). A batch of rAd according to the invention or a composition comprising rAd according to the invention preferably comprises at least 107 rAd particles, and in certain embodiments comprises at least 108, 109, 1010, 1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, or more rAd particles, up to 1020 rAd particles (e.g. as produced in a large scale bioreactor in a single production run). A batch or composition may or may not comprise further relevant components besides the rAd.
The term ‘recombinant’ for a recombinant adenovirus, as used herein implicates that it has been modified by the hand of man as opposed to wild-type adenoviruses, e.g. it comprises a heterologous gene, genes, or parts thereof and a bidirectional mCMV promoter.
Sequences herein are provided in the 5′ to 3′ direction, as is customary in the art.
An “adenovirus capsid protein” refers to a protein on the capsid of an adenovirus that is involved in determining the serotype and/or tropism of a particular adenovirus. Adenoviral capsid proteins typically include the fiber, penton and/or hexon proteins. A rAd of (or ‘based upon’) a certain serotype according to the invention typically comprises fiber, penton and/or hexon proteins of that certain serotype, and preferably comprises fiber, penton and hexon protein of that certain serotype. These proteins are typically encoded by the genome of the rAd. A rAd of a certain serotype may optionally comprise and/or encode other proteins from other adenovirus serotypes.
A rAd is ‘based upon’ an adenovirus as used herein, by derivation from the wild type, at least in sequence. This can be accomplished by molecular cloning, using the wild type genome or parts thereof as starting material. It is also possible to use the known sequence of a wild type adenovirus genome to generate (parts of) the genome de novo by DNA synthesis, which can be performed using routine procedures by service companies having business in the field of DNA synthesis and/or molecular cloning (e.g. GeneArt, GenScripts, Invitrogen, Eurofins). Thus, as a non-limiting example, a rAd that comprises hexon, penton and fiber of Ad35 is considered a rAd based upon Ad35, etc.
The vectors of the present invention are referred to as rAd vectors. The preparation of rAd vectors is well known in the art.
In certain embodiments, a rAd vector according to the invention is deficient in at least one essential gene function of the E1 region, e.g. the E1a region and/or the E1b region, of the adenoviral genome that is required for viral replication. In certain embodiments, an adenoviral vector according to the invention is deficient in at least part of the non-essential E3 region. In certain embodiments, the vector is deficient in at least one essential gene function of the E1 region and at least part of the non-essential E3 region. The adenoviral vector can be “multiply deficient,” meaning that the adenoviral vector is deficient in one or more essential gene functions in each of two or more regions of the adenoviral genome. For example, the aforementioned E1-deficient or E1-, E3-deficient adenoviral vectors can be further deficient in at least one essential gene of the E4 region and/or at least one essential gene of the E2 region (e.g., the E2A region and/or E2B region).
Adenoviral vectors, methods for construction thereof and methods for propagating thereof, are well known in the art and are described in, for example, U.S. Pat. Nos. 5,559,099, 5,837,511, 5,846,782, 5,851,806, 5,994,106, 5,994,128, 5,965,541, 5,981,225, 6,040,174, 6,020,191, 6,113,913, and 8,932,607, and Thomas Shenk, “Adenoviridae and their Replication” M. S. Horowitz, “Adenoviruses”, Chapters 67 and 68, respectively, in Virology, B. N. Fields et al., eds., 3d ed., Raven Press, Ltd., New York (1996), and other references mentioned herein. Typically, construction of adenoviral vectors involves the use of standard molecular biological techniques, such as those described in, for example, Sambrook et al., Molecular Cloning, a Laboratory Manual, 2d ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989), Watson et al., Recombinant DNA, 2d ed., Scientific American Books (1992), and Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, NY (1995), and other references mentioned herein.
An adenovirus according to the invention belongs to the family of the Adenoviridae and preferably is one that belongs to the genus Mastadenovirus. It can be a human adenovirus, but also an adenovirus that infects other species, including but not limited to a bovine adenovirus (e.g. bovine adenovirus 3, BAdV3), a canine adenovirus (e.g. CAdV2), a porcine adenovirus (e.g. PAdV3 or 5), or a simian adenovirus (which includes a monkey adenovirus and an ape adenovirus, such as a chimpanzee adenovirus or a gorilla adenovirus). Preferably, the adenovirus is a human adenovirus (HAdV, or AdHu; in the present invention a human adenovirus is meant if referred to Ad without indication of species, e.g. the brief notation “Ad5” means the same as HAdVS, which is human adenovirus serotype 5), or a simian adenovirus such as chimpanzee or gorilla adenovirus (ChAd, AdCh, or SAdV).
Most advanced studies have been performed using human adenoviruses, and human adenoviruses are preferred according to certain aspects of the invention. In certain preferred embodiments, the recombinant adenovirus according to the invention is based upon a human adenovirus. In preferred embodiments, the recombinant adenovirus is based upon a human adenovirus serotype 5, 11, 26, 34, 35, 48, 49 or 50. According to a particularly preferred embodiment of the invention, an adenovirus is a human adenovirus of one of the serotypes 26, 35. An advantage of these serotypes is a low seroprevalence and/or low pre-existing neutralizing antibody titers in the human population. Preparation of rAd26 vectors is described, for example, in WO 2007/104792 and in (Abbink et al., 2007). Exemplary genome sequences of Ad26 are found in GenBank Accession EF 153474 and in SEQ ID NO:1 of WO 2007/104792. Preparation of rAd35 vectors is described, for example, in U.S. Pat. No. 7,270,811, in WO 00/70071, and in (Vogels et al., 2003). Exemplary genome sequences of Ad35 are found in GenBank Accession AC_000019 and in FIG. 6 of WO 00/70071.
Simian adenoviruses generally also have a low seroprevalence and/or low pre-existing neutralizing antibody titers in the human population, and a significant amount of work has been reported using chimpanzee adenovirus vectors (e.g. U.S. Pat. No. 6,083,716; WO 2005/071093; WO 2010/086189; WO 2010085984; (Bangari & Mittal, 2006; Cohen et al., 2002; Farina et al., 2001; Kobinger et al., 2006; Lasaro & Ertl, 2009; Tatsis et al., 2007). Hence, in other preferred embodiments, the recombinant adenovirus according to the invention is based upon a simian adenovirus, e.g. a chimpanzee adenovirus. In certain embodiments, the recombinant adenovirus is based upon simian adenovirus type 1, 7, 8, 21, 22, 23, 24, 25, 26, 27.1, 28.1, 29, 30, 31.1, 32, 33, 34, 35.1, 36, 37.2, 39, 40.1, 41.1, 42.1, 43, 44, 45, 46, 48, 49, 50 or SA7P.
The sequences of most of the human and non-human adenoviruses mentioned above are known, and for others can be obtained using routine procedures.
A recombinant adenovirus according to the invention may be replication-competent or replication-deficient.
In certain embodiments, the adenovirus is replication deficient, e.g. because it contains a deletion in the E1 region of the genome. A “deletion in the E1 region” means a deletion in this region as compared to a wild-type adenovirus, and means a deletion in at least one of the E1A, E1B 55K or E1B 21K coding regions, preferably a deletion of E1A, E1B 55K and E1B21K coding regions. As known to the skilled person, in case of deletions of essential regions from the adenovirus genome, the functions encoded by these regions have to be provided in trans, preferably by the producer cell, i.e. when parts or whole of E1, E2 and/or E4 regions are deleted from the adenovirus, these have to be present in the producer cell, for instance integrated in the genome thereof, or in the form of so-called helper adenovirus or helper plasmids. The adenovirus may also have a deletion in the E3 region, which is dispensable for replication, and hence such a deletion does not have to be complemented.
A producer cell (sometimes also referred to in the art and herein as ‘packaging cell’ or ‘complementing cell’ or ‘host cell’) that can be used can be any producer cell wherein a desired adenovirus can be propagated. For example, the propagation of recombinant adenovirus vectors is done in producer cells that complement deficiencies in the adenovirus. Such producer cells preferably have in their genome at least an adenovirus E1 sequence, and thereby are capable of complementing recombinant adenoviruses with a deletion in the E1 region. Any E1-complementing producer cell can be used, such as human retina cells immortalized by E1, e.g. 911 or PER.C6 cells (see U.S. Pat. No. 5,994,128), E1-transformed amniocytes (See EP patent 1230354), E1-transformed A549 cells (see e.g. WO 98/39411, U.S. Pat. No. 5,891,690), GH329:HeLa (Gao, Engdahl, & Wilson, 2000), 293, and the like. In certain embodiments, the producer cells are for instance HEK293 cells, or PER.C6 cells, or 911 cells, or IT293SF cells, and the like. For E1-deficient adenoviruses that are not derived from subgroup C or E adenoviruses, it is preferred to exchange the E4-orf6 coding sequence of the non-subgroup C or E adenovirus with the E4-orf6 of an adenovirus of subgroup C such as Ad5. This allows propagation of such adenoviruses in well-known complementing cell lines that express the E1 genes of Ad5, such as for example 293 cells or PER.C6 cells (see, e.g. (Havenga et al., 2006); WO 03/104467, incorporated in its entirety by reference herein).
In alternative embodiments, there is no need to place a heterologous E4orf6 region (e.g. of Ad5) in the adenoviral vector, but instead the E1-deficient non-subgroup C or E vector is propagated in a cell line that expresses both E1 and a compatible E4orf6, e.g. the 293-ORF6 cell line that expresses both E1 and E4orf6 from Ad5 (see e.g. (Brough, Lizonova, Hsu, Kulesa, & Kovesdi, 1996) describing the generation of the 293-ORF6 cells; (Abrahamsen et al., 1997; Nan et al., 2003) each describing generation of E1 deleted non-subgroup C adenoviral vectors using such a cell line).
Alternatively, a complementing cell that expresses E1 from the serotype that is to be propagated can be used (see e.g. WO 00/70071, WO 02/40665).
For subgroup B adenoviruses, such as Ad35, having a deletion in the E1 region, it is preferred to retain the 3′ end of the E1B 55K open reading frame in the adenovirus, for instance the 166 bp directly upstream of the pIX open reading frame or a fragment comprising this such as a 243 bp fragment directly upstream of the pIX start codon (marked at the 5′ end by a Bsu36I restriction site in the Ad35 genome), since this increases the stability of the adenovirus because the promoter of the pIX gene is partly residing in this area (see, e.g. (Havenga et al., 2006); WO 2004/001032, incorporated by reference herein).
“Heterologous nucleic acid” (also referred to herein as ‘transgene’) in adenoviruses of the invention is nucleic acid that is not naturally present in the adenovirus. It is introduced into the adenovirus for instance by standard molecular biology techniques. It may in certain embodiments encode a protein of interest or part thereof. It can for instance be cloned into a deleted E1 or E3 region of an adenoviral vector. In preferred embodiments of the invention, the expression cassette with the two transgenes under control of the bidirectional mCMV promoter is placed into the E1 region of the adenoviral genome. A transgene is generally operably linked to expression control sequences. This can for instance be done by placing the nucleic acid encoding the transgene(s) under the control of a promoter. Many promoters can be used for expression of a transgene(s), and are known to the skilled person.
As used herein, the terms “promoter” or “promoter region” or “promoter element” are used interchangeably, and refer to a segment of a nucleic acid sequence, typically but not limited to DNA, that controls the transcription of the nucleic acid sequence to which it is operatively linked. The promoter region includes specific sequences that are sufficient for RNA polymerase recognition, binding and transcription initiation. In addition, the promoter region can optionally include sequences which modulate this recognition, binding and transcription initiation activity of RNA polymerase. These sequences may be cis-acting or may be responsive to trans-acting factors. Promoters, depending upon the nature of the regulation may be constitutive or regulated. The current invention uses the bidirectional mouse CMV promoter (mCMV) to direct transcription of two different transgenes in a bidirectional fashion.
Further regulatory sequences may also be added. The term “regulatory sequence” is used interchangeably with “regulatory element” herein and refers to a segment of nucleic acid, typically but not limited to DNA, that modulate the transcription of the nucleic acid sequence to which it is operatively linked, and thus acts as a transcriptional modulator. A regulatory sequence often comprises nucleic acid sequences that are transcription binding domains that are recognized by the nucleic acid-binding domains of transcriptional proteins and/or transcription factors, enhancers or repressors etc. For example, a regulatory sequence could include one or more tetracycline operon operator sequences (tetO), such that expression is inhibited in the presence of the tetracycline operon repressor protein (tetR). In the absence of tetracycline, the tetR protein is able to bind to the tetO sites and repress transcription of a gene operably linked to the tetO sites. In the presence of tetracycline, however, a conformational change in the tetR protein prevents it from binding to the operator sequences, allowing transcription of operably linked genes to occur. In certain embodiments, rAd of the present invention can optionally include tetO operatively linked to a bidirectional mouse CMV promoter, such that expression of one or more transgenes is inhibited in rAd that are produced in the producer cell line in which tetR protein is expressed. Subsequently, expression would not be inhibited if the rAd is introduced into a subject or into cells that do not express the tetR protein (see e.g., international patent application WO 07/073513). In certain other embodiments, rAd of the present invention can optionally include a cumate gene-switch system, in which regulation of expression is mediated by the binding of the repressor (CymR) to the operator site (CuO), placed downstream of the promoter (see e.g., (Mullick et al., 2006)).
As used herein, the term “repressor,” refers to entities (e.g., proteins or other molecules) having the capacity to inhibit, interfere, retard and/or repress the production of heterologous protein product of a recombinant expression vector. For example, by interfering with a binding site at an appropriate location along the expression vector, such as in an expression cassette. Examples of repressors include tetR, CymR, the lac repressor, the trp repressor, the gal repressor, the lambda repressor, and other appropriate repressors known in the art.
The recombinant adenoviruses of the present invention comprise a bidirectional mouse CMV (mCMV) promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction. The bidirectional mCMV promoter has been described in detail in European Pat. No. EP1601776, and comprises the mCMV immediate early 1 promoter (IE1) in one direction and the mCMV immediate early 2 promoter (IE2) in opposite direction. It may further comprise enhancers, such as the natural or other enhancers. The natural enhancer for the bidirectional mCMV promoter comprises a major immediate early 1 (MIE1) enhancer and a MIE2 enhancer. Enhancers may also be exchanged for other enhancers that are not naturally present in the mCMV IE region, and/or placed in other positions. Preferably, the enhancer sequences for the promoter in the first direction and the promoter in the other direction do not overlap. The promoter is in a bidirectional architecture, which means that both promoters (i.e. IE1 and IE2 promoters, together constituting the mCMV IE bidirectional promoter) drive expression in opposite orientation, and outward from the center of the two promoters towards the ends of the adenoviral genome, as understood by one skilled in the art. The bidirectional promoter thus will drive expression of the first transgene towards a first end of the adenoviral genome and of the second transgene towards the other end of the adenoviral genome. Schematic representations of rAd and rAd vector constructs of the present invention are provided in
The terms “operably linked”, or “operatively linked” are used interchangeably herein, and refer to the functional relationship of the nucleic acid sequences with regulatory sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences and indicates that two or more DNA segments are joined together such that they function in concert for their intended purposes. For example, operative linkage of nucleic acid sequences, typically DNA, to a regulatory sequence or promoter region refers to the physical and functional relationship between the DNA and the regulatory sequence or promoter such that the transcription of such DNA is initiated from the regulatory sequence or promoter, by an RNA polymerase that specifically recognizes, binds and transcribes the DNA. In order to optimize expression and/or in vitro transcription, it may be necessary to modify the regulatory sequence for the expression of the nucleic acid or DNA in the cell type for which it is expressed. The desirability of, or need of, such modification may be empirically determined.
The mCMV IE1 part of the bidirectional promoter provides stronger expression than the mCMV IE2 part of the bidirectional promoter (about 10× expression level difference, as tested for luciferase), and therefore the transgene for which the highest expression is desired can be placed under control of the mCMV IE1 part of the bidirectional promoter. However, with expression controlled by either part of the bidirectional promoter the transgene is potently expressed. As used herein, “potently expressed” or “potent expression” mean that the expression, as measured by different protein detection techniques such as Western Blot or FACS analysis, is comparable to or even better than expression from monovalent rAd expressing a single antigen under the control of an hCMV promoter. For example, the expression level as determined by FACS analysis of both antigens from the bidirectional mCMV promoter of the present invention is preferably at least 60%, 70%, 80%, 90%, or 95% of the antigen expression level from a monovalent rAd with an hCMV promoter. In certain embodiments, the expression level of both antigens from the bidirectional mCMV is 100% of the antigen expression level from a monovalent rAd with an hCMV promoter. Furthermore, it is known from rAd expressing a single antigen under the control of an hCMV promoter that the expression is sufficient to generate significant T-cell and B-cell immune responses. Therefore, potent expression of two transgenes expressed by an mCMV bidirectional promoter of the present invention is expected to generate a significant T-cell and B-cell immune response to both transgenes. For example, if the two transgenes encode antigens to elicit an immune response when administered to a subject, potent expression will generate a measurable immune response against both antigens and that immune response will preferably be the same or better than the immune response generated by an rAd with a single transgene expressing a single antigen under the control of a hCMV promoter.
The terms “coding sequence”, sequence encoding, or “encoding” are used interchangeably herein, and refer to the nucleic acid sequence which is transcribed (DNA) and translated (mRNA) into a polypeptide in vitro or in vivo when operably linked to appropriate regulatory sequences.
A polyadenylation signal, for example the bovine growth hormone polyA signal (U.S. Pat. No. 5,122,458), may be present behind the transgenes. Preferably, each transgene has a polyA signal, and preferably the polyA signal for the first transgene is different from the polyA signal for the second transgene. In one embodiment, a first polyA signal is an SV40 polyA signal, and a second polyA signal is the bovine growth hormone polyA signal.
In preferred embodiments, a sequence comprising an intron is positioned downstream (3′) of the promoter and upstream (5′) of the first transgene, and a further sequence comprising an intron is positioned downstream of the promoter and upstream of the second transgene. These introns may be the same or different. An intron as used herein has the normal function and structure as known in the art, and is a polynucleotide sequence in a nucleic acid that does not encode information for protein synthesis and is removed before translation of messenger RNA, by a process known as splicing. An intron comprises a splice donor site (5′ end of the intron, usually a GU sequence) and a splice acceptor site (3′ end of the intron, usually a GA sequence). A schematic representation of the architecture of the constructs according to the invention comprising introns is provided in
One of the exemplified parameters in the experiments described herein is immunogenicity, which is relevant for antigens in a vaccine application. However, it will be immediately clear to the skilled person that transgene expression levels can also be relevant for transgenes for which an immune response is not the primary goal, e.g. for transgenes that are used in gene therapy purposes. Hence, the invention can be practiced with any combination of transgenes for which expression from a single recombinant adenoviral vector is desired. Therefore, the identity of the transgene is not material for the instant invention, which is suitable for adenoviruses comprising any transgene. Suitable transgenes are well known to the skilled person, and for instance may include transgene open reading frames, for instance open reading frames coding for polypeptides that have a therapeutic effect, e.g. for gene therapy purposes, or polypeptides against which an immune response is desired when the rAd vector is used for vaccination purposes. Particularly preferred heterologous nucleic acids are genes of interest encoding antigenic determinants towards which an immune response needs to be raised. Such antigenic determinants are also typically referred to as antigens. When the recombinant adenovirus is administered to a subject, an immune response will be raised against the antigen(s). Any desired antigen can be encoded by the adenovirus vector. In typical embodiments according to the invention, antigens are peptides, polypeptides or proteins from organisms that may cause a disease or condition. Therefore, in a further preferred embodiment, said heterologous nucleic acid of interest encodes an immunogenic (or antigenic) determinant. More preferably, said immunogenic determinant is an antigen from a bacterium, a virus, yeast or a parasite. The diseases caused by such organisms are generally referred to as ‘infectious disease’ (and are thus not limited to organisms that ‘infect’ but also include those that enter the host and cause a disease). So-called ‘self-antigens’, e.g. tumour antigens, also form part of the state of the art, and may be encoded by heterologous nucleic acids in the recombinant adenoviruses according to the present invention. Non-limiting examples from which the antigenic determinants (or antigens) are taken are malaria-causing organisms, such as Plasmodium falciparum, tuberculosis-causing organism such as Mycobacterium tuberculosis, yeasts, or viruses. In other preferred embodiments, antigens from viruses such as flaviviruses (e.g., West Nile Virus, Hepatitis C Virus, Japanese Encephalitis Virus, Dengue Virus), Ebola virus, Human Immunodeficiency Virus (HIV), and Marburg virus may be used in compositions according to the present invention. In one embodiment, said antigen is the CS protein or immunogenic part thereof from P. falciparum (for examples of adenovirus vectors encoding CS, see e.g. (Havenga et al., 2006; Ophorst et al., 2006); WO 2004/055187, all incorporated in their entirety by reference herein). In another embodiment, the antigenic determinant is a protein of one antigen-, or a fusion protein of several antigens from M. tuberculosis, such as the Ag85A, Ag85B and/or the TB10.4 proteins or immunogenic part(s) thereof (see for the construction and production of such TB vaccine viruses e.g. WO 2006/053871, incorporated by reference herein). In yet another embodiment, said antigenic determinant is a viral glycoprotein or immunogenic part thereof, such as GP from a filovirus, such as Ebola virus or Marburg virus (e.g. (Geisbert et al., 2011; Sullivan et al., 2006; Sullivan et al., 2003). In yet further embodiments, said immunogenic determinant is from an HIV protein such as gag, pol, env, nef, or variants thereof (for examples of adenovirus based HIV vaccines, see e.g. WO 2009/026183, WO 2010/096561, WO 2006/120034, WO 02/22080, WO 01/02607). In other embodiments, said antigenic determinant is a HA, NA, M, or NP protein, or immunogenic part of any of these, from influenza virus (e.g. (Hu et al., 2011; Zhou et al., 2010); review by (Vemula & Mittal, 2010)). In other embodiments, the antigenic determinant is a HA protein or immunogenic part thereof from a measles virus (e.g. WO 2004/037294). In other embodiments, the antigenic determinant is rabies virus glycoprotein (e.g. (Zhou, Cun, Li, Xiang, & Ertl, 2006)). In further embodiments, the antigen is from a respiratory syncytial virus (RSV), e.g. RSV F protein (see e.g. WO 2013/139911 and WO 2013/139916), or RSV G protein, or both, or other RSV proteins. In other embodiments, the antigen is from another virus such as human papillomavirus or other viruses, etc. The recombinant adenovirus may encode two different antigens from the same organism. The recombinant adenovirus may also encode combinations of antigens from different organisms, e.g. a first antigen from a first organism and second antigen from a second organism. It is also possible to encode an antigen and for instance an adjuvant into the same adenovirus, e.g. an antigen and a Toll-Like-Receptor (TLR) agonist, such as a TLR3 agonist, such as dsRNA or a mimetic thereof or the like (e.g. WO 2007/100908). In certain embodiments, the recombinant adenovirus encodes two different antigens, each under control of the bidirectional mCMV promoter. In other embodiments, the recombinant adenovirus encodes an antigen and an immune modulator, each under control of the bidirectional mCMV promoter. In certain embodiments, further heterologous sequences or transgenes may be present in the recombinant adenovirus, besides the first and second transgene that are under control of the bidirectional mCMV promoter.
The invention also provides a method for producing a genetically stable recombinant adenovirus comprising a first and a second transgene that each are potently expressed when the adenovirus infects a target cell, the method comprising: preparing a construct comprising a bidirectional mCMV promoter operably linked to a first transgene in one direction and to a second transgene in the opposite direction, and incorporating said construct into the genome of the recombinant adenovirus. The preparation of the construct as such encompasses the use of standard molecular cloning methods (see e.g. (Holterman et al., 2004; Lemckert et al., 2006; Vogels et al., 2003); Sambrook, Fritsch and Maniatis, Molecular Cloning: A Laboratory Manual, 2nd edition, 1989; Current Protocols in Molecular Biology, Ausubel F M, et al, eds, 1987; the series Methods in Enzymology (Academic Press, Inc.); PCR2: A Practical Approach, MacPherson M J, Hams B D, Taylor G R, eds, 1995), as known to the skilled person and routinely performed in the field of recombinant adenovirus technology, and exemplified herein. The bidirectional mCMV promoter has the features as described above, and can be obtained by routine methods (see e.g. European Pat. No. EP1601776). For convenience, the skilled person may manipulate the adenovirus genome by cloning into smaller fragments, e.g. a first part for the left part of the genome up to the E1 region for easy manipulation and introduction of the transgenes in plasmid form and a second, larger, part for the remainder of the genome that can upon recombination with the first part result in a complete adenovirus genome (see e.g. WO 99/55132).
The rAd of the present invention has the advantage that it can express two transgenes and remains genetically stable, unlike adenoviruses prepared by the various alternative approaches for expressing two transgenes that are provided in the prior art. Thus, the bidirectional mCMV promoter solves the problem of genetic instability of adenoviruses that express two transgenes.
To measure genetic stability, rAd are rescued and passaged in an appropriate cell line, e.g., helper cell line PER.C6®. Viral DNA is isolated at certain passage numbers and the integrity of the rAd genome can be analyzed by one or more of the following: PCR analysis for presence or absence of deletion bands, restriction digests of the rAd genome for presence or absence of differences in restriction fragments, and/or sequencing of the rAd genome or of PCR-products of the rAd genome for presence or absence of mutations in the rAd sequences. With regard to the rAd of the present invention, “genetically stable” means that the nucleotide sequence does not change from the plasmids used for generation of the rAd to later production stages of the rAd, such that rAd expressing two transgenes has the same genetic stability as a comparable rAd with a single transgene (behind a hCMV promoter) as suitable for large scale batch productions. For example, PCR analysis using primers flanking the expression cassette does not show deletion fragments (bands) compared to earlier passage numbers of the rAd or the starting material and/or sequencing the PCR product of the E1, E3 and E4 regions confirms that the nucleotide sequence does not change. Genetic stability is thoroughly assessed in this study compared to other testing methods such as test digestions on a single produced virus batch. Sensitivity of the assay is increased by the following means: several viral populations (plaques) are isolated and subjected to extended passaging. The extended passaging, combined with a PCR analysis using primers flanking the expression cassette allows for detection of a small proportion of deletion mutants in the rAd population which might be overlooked using other methods. Further, sequencing analysis is performed to exclude occurrence of point mutations, such as introduction of stop codons in the open reading frame of the transgene. More specifically, since viral mutations always present a chance event, one plaque may be stable whereas another one may present a deletion band. Therefore, to correctly assess genetic stability, several viral populations (plaques) need to be tested. In case a mutation occurs, which enables the vector to replicate more efficiently than the parental vector, this can lead to outgrowth of the mutant version, which is often only observed following extended passaging as described in this study. Preferably, the rAd of the present invention are genetically stable for at least up to 10 passages, and even more preferably for at least up to 13 passages in the test system used, such that the virus is sufficiently stable for large scale production campaigns.
The recombinant adenovirus produced according to the methods of the invention can be prepared according to the embodiments described above for the recombinant adenovirus.
The invention also provides a method for expressing at least two transgenes in a cell, the method comprising providing the cell with a recombinant adenovirus according to the invention. Providing a cell with a recombinant adenovirus can be done via administration of the adenovirus to a subject, or via introduction (e.g. infection) of the adenovirus in vitro or ex vivo into a cell. In certain embodiments the invention provides a recombinant adenoviral vector for use in expressing at least two transgenes in a cell, e.g. by administering the recombinant adenovirus to a subject.
The invention also provides a method for inducing an immune response against at least two antigens, comprising administering to a subject a recombinant adenovirus according to the invention. The invention also provides a recombinant adenovirus according to the invention for use in inducing an immune response against at least two antigens.
The invention also provides a recombinant DNA molecule comprising the genome of a recombinant adenovirus of the invention. The skilled person will be aware that this may also be a combination of at least two different recombinant DNA molecules that together can form the single recombinant DNA molecule of the invention. Such molecules are useful in manipulating the genome and creating novel recombinant adenoviruses. The genome encodes the proteins that are required for adenovirus replication and packaging in permissive cells.
The term ‘about’ for numerical values as used in the present disclosure means the value±10%.
Producer cells are cultured to increase cell and virus numbers and/or virus titers. Culturing a cell is done to enable it to metabolize, and/or grow and/or divide and/or produce virus of interest according to the invention. This can be accomplished by methods such as well-known to persons skilled in the art, and includes but is not limited to providing nutrients for the cell, for instance in the appropriate culture media. Suitable culture media are well known to the skilled person and can generally be obtained from commercial sources in large quantities, or custom-made according to standard protocols. Culturing can be done for instance in dishes, roller bottles or in bioreactors, using batch, fed-batch, continuous systems and the like. Suitable conditions for culturing cells are known (see e.g. Tissue Culture, Academic Press, Kruse and Paterson, editors (1973), and R. I. Freshney, Culture of animal cells: A manual of basic technique, fourth edition (Wiley-Liss Inc., 2000, ISBN 0-471-34889-9).
Typically, the adenovirus will be exposed to the appropriate producer cell in a culture, permitting uptake of the virus. Usually, the optimal agitation is between about 50 and 300 rpm, typically about 100-200, e.g. about 150, typical DO is 20-60%, e.g. 40%, the optimal pH is between 6.7 and 7.7, the optimal temperature between 30 and 39° C., e.g. 34-37° C., and the optimal MOI between 5 and 1000, e.g. about 50-300. Typically, adenovirus infects producer cells spontaneously, and bringing the producer cells into contact with rAd particles is sufficient for infection of the cells. Generally, an adenovirus seed stock is added to the culture to initiate infection, and subsequently the adenovirus propagates in the producer cells. This is all routine for the person skilled in the art.
After infection of an adenovirus, the virus replicates inside the cell and is thereby amplified, a process referred to herein as propagation of adenovirus. Adenovirus infection results finally in the lysis of the cells being infected. The lytic characteristics of adenovirus therefore permits two different modes of virus production. The first mode is harvesting virus prior to cell lysis, employing external factors to lyse the cells. The second mode is harvesting virus supernatant after (almost) complete cell lysis by the produced virus (see e.g. U.S. Pat. No. 6,485,958, describing the harvesting of adenovirus without lysis of the host cells by an external factor). It is preferred to employ external factors to actively lyse the cells for harvesting the adenovirus.
Methods that can be used for active cell lysis are known to the person skilled in the art, and have for instance been discussed in WO 98/22588, p. 28-35. Useful methods in this respect are for example, freeze-thaw, solid shear, hypertonic and/or hypotonic lysis, liquid shear, sonication, high pressure extrusion, detergent lysis, combinations of the above, and the like. In one embodiment of the invention, the cells are lysed using at least one detergent. Use of a detergent for lysis has the advantage that it is an easy method, and that it is easily scalable.
Detergents that can be used, and the way they are employed, are generally known to the person skilled in the art. Several examples are for instance discussed in WO 98/22588, p. 29-33. Detergents can include anionic, cationic, zwitterionic, and nonionic detergents. The concentration of the detergent may be varied, for instance within the range of about 0.1%-5% (w/w). In one embodiment, the detergent used is Triton X-100.
Nuclease may be employed to remove contaminating, i.e. mostly from the producer cell, nucleic acids. Exemplary nucleases suitable for use in the present invention include Benzonase®, Pulmozyme®, or any other DNase and/or RNase commonly used within the art. In preferred embodiments, the nuclease is Benzonase®, which rapidly hydrolyzes nucleic acids by hydrolyzing internal phosphodiester bonds between specific nucleotides, thereby reducing the viscosity of the cell lysate. Benzonase® can be commercially obtained from Merck KGaA (code W214950). The concentration in which the nuclease is employed is preferably within the range of 1-100 units/ml. Alternatively, or in addition to nuclease treatment, it is also possible to selectively precipitate host cell DNA away from adenovirus preparations during adenovirus purification, using selective precipitating agents such as domiphen bromide (see e.g. U.S. Pat. No. 7,326,555; (Goerke, To, Lee, Sagar, & Konz, 2005); WO 2011/045378; WO 2011/045381).
Methods for harvesting adenovirus from cultures of producer cells have been extensively described in WO 2005/080556.
In certain embodiments, the harvested adenovirus is further purified. Purification of the adenovirus can be performed in several steps comprising clarification, ultrafiltration, diafiltration or separation with chromatography as described in for instance WO 05/080556, incorporated by reference herein. Clarification may be done by a filtration step, removing cell debris and other impurities from the cell lysate. Ultrafiltration is used to concentrate the virus solution. Diafiltration, or buffer exchange, using ultrafilters is a way for removal and exchange of salts, sugars and the like. The person skilled in the art knows how to find the optimal conditions for each purification step. Also WO 98/22588, incorporated in its entirety by reference herein, describes methods for the production and purification of adenoviral vectors. The methods comprise growing host cells, infecting the host cells with adenovirus, harvesting and lysing the host cells, concentrating the crude lysate, exchanging the buffer of the crude lysate, treating the lysate with nuclease, and further purifying the virus using chromatography.
Preferably, purification employs at least one chromatography step, as for instance discussed in WO 98/22588, p. 61-70. Many processes have been described for the further purification of adenoviruses, wherein chromatography steps are included in the process. The person skilled in the art will be aware of these processes, and can vary the exact way of employing chromatographic steps to optimize the process. It is for instance possible to purify adenoviruses by anion exchange chromatography steps, see for instance WO 2005/080556. Many other adenovirus purification methods have been described and are within the reach of the skilled person. Further methods for producing and purifying adenoviruses are disclosed in for example WO 00/32754, WO 04/020971, U.S. Pat. Nos. 5,837,520, 6,261,823, and WO 2006/108707, all incorporated by reference herein.
For administering to humans, the invention may employ pharmaceutical compositions comprising the rAd and a pharmaceutically acceptable carrier or excipient. In the present context, the term “Pharmaceutically acceptable” means that the carrier or excipient, at the dosages and concentrations employed, will not cause any unwanted or harmful effects in the subjects to which they are administered. Such pharmaceutically acceptable carriers and excipients are well known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A. R. Gennaro, Ed., Mack Publishing Company [1990]; Pharmaceutical Formulation Development of Peptides and Proteins, S. Frokjaer and L. Hovgaard, Eds., Taylor & Francis [2000]; and Handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed., Pharmaceutical Press [2000]). The purified rAd preferably is formulated and administered as a sterile solution although it is also possible to utilize lyophilized preparations. Sterile solutions are prepared by sterile filtration or by other methods known per se in the art. The solutions are then lyophilized or filled into pharmaceutical dosage containers. The pH of the solution generally is in the range of pH 3.0 to 9.5, e.g pH 5.0 to 7.5. The rAd typically is in a solution having a suitable buffer, and the solution of rAd may also contain a salt. Optionally stabilizing agent may be present, such as albumin. In certain embodiments, detergent is added. In certain embodiments, rAd may be formulated into an injectable preparation. These formulations contain effective amounts of rAd, are either sterile liquid solutions, liquid suspensions or lyophilized versions and optionally contain stabilizers or excipients. An adenovirus vaccine can also be aerosolized for intranasal administration (see e.g. WO 2009/117134).
For instance adenovirus may be stored in the buffer that is also used for the Adenovirus World Standard (Hoganson et al., 2002): 20 mM Tris pH 8, 25 mM NaCl, 2.5% glycerol. Another useful formulation buffer suitable for administration to humans is 20 mM Tris, 2 mM MgCl2, 25 mM NaCl, sucrose 10% w/v, polysorbate-80 0.02% w/v. Another formulation buffer that is suitable for recombinant adenovirus comprises 10-25 mM citrate buffer pH 5.9-6.2, 4-6% (w/w) hydroxypropyl-beta-cyclodextrin (HBCD), 70-100 mM NaCl, 0.018-0.035% (w/w) polysorbate-80, and optionally 0.3-0.45% (w/w) ethanol. Obviously, many other buffers can be used, and several examples of suitable formulations for the storage and for pharmaceutical administration of purified (adeno)virus preparations are known, including those that can for instance be found in European patent no. 0853660, U.S. Pat. No. 6,225,289 and in international patent applications WO 99/41416, WO 99/12568, WO 00/29024, WO 01/66137, WO 03/049763, WO 03/078592, WO 03/061708.
In certain embodiments a composition comprising the adenovirus further comprises one or more adjuvants. Adjuvants are known in the art to further increase the immune response to an applied antigenic determinant, and pharmaceutical compositions comprising adenovirus and suitable adjuvants are for instance disclosed in WO 2007/110409, incorporated by reference herein. The terms “adjuvant” and “immune stimulant” are used interchangeably herein, and are defined as one or more substances that cause stimulation of the immune system. In this context, an adjuvant is used to enhance an immune response to the adenovirus vectors of the invention. Examples of suitable adjuvants include aluminium salts such as aluminium hydroxide and/or aluminium phosphate; oil-emulsion compositions (or oil-in-water compositions), including squalene-water emulsions, such as MF59 (see e.g. WO 90/14837); saponin formulations, such as for example QS21 and Immunostimulating Complexes (ISCOMS) (see e.g. U.S. Pat. No. 5,057,540; WO 90/03184, WO 96/11711, WO 2004/004762, WO 2005/002620); bacterial or microbial derivatives, examples of which are monophosphoryl lipid A (MPL), 3-O-deacylated MPL (3dMPL), CpG-motif containing oligonucleotides, ADP-ribosylating bacterial toxins or mutants thereof, such as E. coli heat labile enterotoxin LT, cholera toxin CT, and the like. It is also possible to use vector-encoded adjuvant, e.g. by using heterologous nucleic acid that encodes a fusion of the oligomerization domain of C4-binding protein (C4 bp) to the antigen of interest (Ogun, Dumon-Seignovert, Marchand, Holder, & Hill, 2008), or heterologous nucleic acid encoding a toll-like receptor (TLR) agonist, such as a TLR3 agonist such as dsRNA (see e.g. WO 2007/100908) or the like. Such rAd according to the invention may for instance encode an antigen of interest on one side of the bidirectional promoter and a TLR3 agonist on the other side of the bidirectional promoter. Such rAd are particularly suited for administration via a mucosal route, e.g. oral administration (see e.g. WO 2007/100908). In certain embodiments the compositions of the invention comprise aluminium as an adjuvant, e.g. in the form of aluminium hydroxide, aluminium phosphate, aluminium potassium phosphate, or combinations thereof, in concentrations of 0.05-5 mg, e.g. from 0.075-1.0 mg, of aluminium content per dose.
In other embodiments, the compositions do not comprise adjuvants.
A pharmaceutical composition according to the invention may in certain embodiments be a vaccine.
Adenovirus compositions may be administered to a subject, e.g. a human subject. The total dose of the adenovirus provided to a subject during one administration can be varied as is known to the skilled practitioner, and is generally between 1×107 viral particles (vp) and 1×1012 vp, preferably between 1×108 vp and 1×1011 vp, for instance between 3×108 and 5×1010 vp, for instance between 109 and 3×1019 vp.
Administration of adenovirus compositions can be performed using standard routes of administration. Non-limiting embodiments include parenteral administration, such as by injection, e.g. intradermal, intramuscular, etc, or subcutaneous or transcutaneous, or mucosal administration, e.g. intranasal, oral, and the like. In one embodiment a composition is administered by intramuscular injection, e.g. into the deltoid muscle of the arm, or vastus lateralis muscle of the thigh. The skilled person knows the various possibilities to administer a composition, e.g. a vaccine in order to induce an immune response to the antigen(s) in the vaccine.
A subject as used herein preferably is a mammal, for instance a rodent, e.g. a mouse, or a non-human-primate, or a human. Preferably, the subject is a human subject.
It is also possible to provide one or more booster administrations of one or more adenovirus vaccines. If a boosting vaccination is performed, typically, such a boosting vaccination will be administered to the same subject at a moment between one week and one year, preferably between two weeks and four months, after administering the composition to the subject for the first time (which is in such cases referred to as ‘priming vaccination’). In alternative boosting regimens, it is also possible to administer different vectors, e.g. one or more adenoviruses of different serotype, or other vectors such as MVA, or DNA, or protein, to the subject as a priming or boosting vaccination.
Various publications, which may include patents, published applications, technical articles and scholarly articles, are cited throughout the specification in parentheses, and full citations of each may be found at the end of the specification. Each of these cited publications is incorporated by reference herein, in its entirety.
Other embodiments, features, and advantages of the invention are further illustrated by reference to the following examples. The examples do not limit the invention in any way. They merely serve to clarify the invention.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working examples therefore, specifically point out certain embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
Generation of E1 Adapter Plasmids Containing Filovirus Glycoproteins
Filovirus glycoprotein encoding genes for Marburg virus Angola (MARV) (GenBank® accession number Q1PD50), Ebola virus Zaire strain Mayinga (EBOV) (GenBank® accession number AAN37507.1 with a T544I mutation), and Ebola virus Sudan Gulu (SEBOV) (GenBank® accession number YP_138523 with G2E) were gene-optimized for human expression and cloned into pAdapt35 or pAdapt26 plasmids (Vogels et al. 2007; Abbink et al., 2007), using restriction sites HindIII and Xbal. A Kozak sequence (5′ GCCACC 3′) was included directly in front of the ATG start codon, and two stop codons (5′ TGA TAA 3′) were added at the end of the coding sequences. As described herein, the recombinant adenoviruses and vectors are referred to generally as rAd or rAd vectors and more specifically as rAd35 or rAd26.
Cell Culture:
PER.C6 cells (Fallaux et al., 1998) were maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), supplemented with 10 mM MgCl2.
Adenovirus Generation, Infections and Passaging.
All adenoviruses were generated in PER.C6® cells by homologous recombination and produced as previously described (for rAd35: (Havenga et al., 2006); for rAd26: (Abbink et al., 2007)). Briefly, PER.C6® cells were transfected with rAd vector encoding plasmids, using Lipofectamine according to the instructions provided by the manufacturer (Life Technologies). For rescue of rAd35 vectors carrying the filovirus glycoprotein transgene expression cassette, the pAdApt35 plasmids and pWE/Ad35.pIX-rITR.dE3.5orf6 cosmid were used, whereas for rAd26 vectors, the pAdApt plasmids and pWE.Ad26.dE3.5orf6. cosmid were used. Cells were harvested one day after full cytopathic effect (CPE), freeze-thawed, centrifuged for 5 min at 3,000 rpm, and stored at −20° C. Next the viruses were plaque purified and amplified in PER.C6® cultured on a single well of a multiwell 24 tissue culture plate. Further amplification was carried out in PER.C6® cultured using a T25 tissue culture flask.
Genetic Stability Testing of Adenoviral Vectors in PER.C6® Cells.
Genetic stability testing of the vaccine vectors was performed to ensure genetic stability in the production process, which involves several passages in PER.C6® cells as illustrated in
Monovalent rAd.E1 or single-insert vectors using genetic designs as depicted in
As a first example of a published strategy to generate bivalent adenoviral vectors, the E1-E3 strategy was tested as depicted in
An E1-F2A strategy (depicted in
Therefore, to allow for further evaluation of viruses with the bicistronic E1-F2A design, in particular to evaluate expression levels and immunogenicity of the two transgenes, T25 material of the generated Ad35.E1.MARV-F2A-SEBOV virus was used to inoculate a T175 tissue culture flask. Of the T175 crude lysate, 3 to 5 ml was used to inoculate 20×T175 triple-layer tissue culture flasks containing 70% confluent layers of PER. C6® cells. The virus was then purified using a two-step CsCl purification method and the purified virus was stored in aliquots at 85° C.
Further, viral vectors were generated using a TaV sequence, a 2A sequence derived from Thosea assigna virus and expressing eGFP and luciferase, rAd35.E1.eGFP—TaV-Luc, rAd35.E1.Luc-TaV-eGFP. Expression analysis by Western Blot showed a similar reduction in expression as observed for the F2A constructs. Genetic stability testing also showed comparable results as for F2A constructs. This approach was not further pursued.
For both gene therapy and vaccine applications, potent expression of the encoded transgene is a prerequisite, e.g., for a vaccine to be sufficiently immunogenic there needs to be sufficient expression of the transgenes (antigens) to stimulate T-cell and/or B-cell responses. Since single-insert vaccine vectors as presented in
Since the filovirus glycoproteins (GPs), MARV and SEBOV, are surface transmembrane proteins, correct posttranslational modifications and trafficking are considered important for immunogenicity. Therefore, expression on the cell surface of rAd infected cells was tested in a FACS cell surface expression assay. To this end, A549 cells were infected with bivalent rAd35.E1.MARV-F2A-SEBOV expressing both MARV and SEBOV and with a mixture of the two monovalent vectors rAd35.MARV and rAd35.SEBOV as a benchmark control. Cells were infected with increasing amount of virus (111, 333 and 1000 VP/cell), harvested 48 hours post infection (48 hpi), and GPs on the cell surface were stained using mouse-serum raised against the respective GPs. An anti-mouse APC-coupled secondary antibody was used to facilitate detection of the cells by FACS. % of APC-positive cells was counted. The results presented in
To analyze the immune response induced against the encoded transgenes by bivalent rAd35.E1.MARV-F2A-SEBOV, mice were immunized with the purified vaccine vector, using the mix of the two monovalent vectors rAd35.MARV and rAd35.SEBOV as a benchmark control. In this study, animals were distributed in experimental groups of 10 mice. A single dose of 1×109 vector particles (VP) per vector was administered intramuscularly. To compensate for a possible adjuvanting effect in mice injected with 2 single-insert vectors (thus receiving 2×109 VP per animal), animals injected with rAd35.E1.MARV-F2A-SEBOV were also administered 1×109 VP of Ad35.empty vector (thus all mice received 2×109 total VP per animal). The readout for cellular and humoral immune response was an ELISPOT and ELISA at 8 weeks post-immunization.
The ELISPOT assay is used to determine the relative number of GP protein-specific IFNγ-secreting T-cells in the spleen, and is essentially done as described in (Radosevic et al., 2010), with some adaptations. In brief, for stimulation in ELISPOT three different 15-mer peptide pools per Filovirus antigen were used; a consensus pool which contains peptides similar between either the Ebola or Marburg Filovirus glycoproteins, Pool 1 containing the remaining peptides from the N-terminal half of the specific glycoproteins and Pool 2 with peptides containing the remaining peptides from the C-terminal part of the specific Filovirus glycoprotein. The designed overlapping peptides were fully matched to the glycoprotein encoded by the rAd vectors. The numbers of spot-forming units (SFU) per 106 cells were calculated.
For the determination of GP specific antibody titers an SEBOV or MARV glycoprotein specific mouse antibody ELISA was used. ELISA Maxisorp plates (Nunc) were coated overnight (ON) at 4° C. with 10 μg/ml L-PBS, Lectin in PBS (pH 7.4 Gibco). The plates were subsequently blocked for two hours at room temperature (RT) using blocking buffer and coated with in PBS diluted SEBOV and MARV containing HEK293 supernatant. After washing with the wash buffer, the diluted reference standard serum and the test serum were added (in duplicate) to the plates with sample buffer and incubated at RT for one hour. As a negative control naïve mouse serum is taken along. The plates were washed again with wash buffer, coated with anti-mouse IgG-HRP diluted in sample buffer, incubated at RT for 1 hour and developed using OPD (Sigma) solution according to the manufacturers recommendations. After stopping the enzymatic reaction with 1M H2SO4 the OD was measured at 492 nm using an ELISA plate reader. All the analyses were performed using the GenS software. The serum concentrations in a test sample were reported in ELISA units per milliliter (EU/ml) with the following inclusion and exclusion criteria; the variation of OD between the duplicates in each sample >20% the sample was excluded, the average OD of the naïve serum should be lower than 0.5 and finally per serum sample at least two dilutions should be above OD 0.5 to obtain the correct EU/ml.
From the experiments presented in
As a third strategy to generate bivalent rAd vectors it was tested whether two expression cassettes could be inserted in a head-to-tail configuration in the E1 region. A schematic representation of the design is shown in
Transgene expression from the rAd with head-to-tail transgene configuration in E1 driven by the heterologous promoters was tested by Western Blot and the expression was compared to the above described benchmark single insert vectors as indicated in
As an additional control of correct processing and presentation of the glycoprotein transgenes, surface staining by FACS (% of positive cells) of vector rAd35.mCAG.MARV-hCMV.SEBOV transduced A549 cells (111, 333 and 1000 VP/cell) was performed with the respective antigen specific antibodies. The direct comparison with the single insert benchmark controls, rAd35.SEBOV and rAd35.MARV, shows higher levels of surface associated MARV and lower levels of surface associated SEBOV were produced by the rAd35.mCAG.MARV-hCMV.SEBOV vector (
rAd35.mCAG.MARV-hCMV.SEBOV was further tested for immunogenicity in mice. 10 mice per group, were intramuscularly immunized with a single dose (1×109) of purified vaccine vector and directly compared to a mix of the two monovalent vectors rAd35.MARV and rAd35.SEBOV. Humoral and cellular immune responses were analyzed by ELISPOT and ELISA 8 weeks post immunization (
Finally, the fourth option to generate multivalent rAd was designed where two genes of choice can be inserted in the E1 region. In contrast to the previously discussed designs, the antigens are driven by a bidirectional promoter (Pbidir or bidir) and placed in an inverted orientation on the 5′ side of the promoter and in the right orientation on the 3′ side. Since the objective was to find a bidirectional promoter expressing similar levels of both encoded transgenes, denoted here as a balanced transgene expression, several different bidirectional promoter designs were tested for potency and balance of transgene expression (
Transient reporter gene expression in HEK293 cells, illustrate the bidir3 promoter to be the most potent and balanced promoter. When directly compared to the bidir1 and bidir2 promoters the most balanced expression of Luc and eGFP was found for the bidir3 promoter. In regard to potency, both bidir1 and bidir2 promoters were outperformed by the reporter genes expression levels recorded for the bidir3 promoter (
To confirm the results obtained with the transient transfections in HEK293 cells, rAd35.eGFP-bidir3-Luc and rAd35.Luc-bidir3-eGFP adenoviral vectors were generated and the expression of the reporter genes was tested in A549 cells infected with 1000 VP/cell (
Thus it was determined that an rAd with a bidirectional mouse CMV promoter is superior to previously reported bivalent rAd with regard to levels of expression of the two transgenes, eGFP and Luc. Furthermore, expression of the two transgenes from rAd with a bidir3 bidirectional promoter was also better than the benchmark monovalent vectors that were tested. Therefore, it was determined that the rAd with a bidir3 bidirectional promoter would be suitable for use in gene therapy or vaccine applications with regard to levels of expression of the transgenes.
A representative design of an mCMV IE1/IE2 promoter is shown in
A selected mCMV bidirectional promoter is schematically represented in
The different rAd vectors were also evaluated for rescueability in PER.C6® cells and genetic stability at p13. The data are summarized in Table 2. The genetic stability was assessed for each vector by passaging the five plaques in PER.C6® up to p13. All vectors were found to be genetically stable at p13, with no deletion bands (
Subsequently the expression levels of rAd35.MARV-mCMV-SEBOV were evaluated for both total expression (Western Blot,
Next, the immunogenicity of rAd35.MARV-mCMV-SEBOV (2×109 VP) was directly compared to a mixture of the respective single insert controls, rAd35.E1.MARV+rAd35.E1.SEBOV (2×109 VP), by looking at the induced MARV and SEBOV specific T-cell responses and B-cell responses (
Thus, according to the results presented above for rAd35.MARV-mCMV-SEBOV, it was determined that an rAd35 with a bidirectional mouse CMV promoter expressing MARV and SEBOV is superior to previously reported bivalent rAd with regard to genetic stability, levels of expression of the two transgenes, and immunogenicity. Furthermore, it was determined that rAd35 with a bidirectional mouse CMV promoter provide sufficient expression levels of both transgenes to generate significant T-cell and B-cell immune responses to both antigens. Therefore, it was determined that the rAd35 with a bidirectional mouse CMV promoter would be suitable for use in gene therapy and vaccine applications with regard to genetic stability, levels of expression of the transgenes, and immunogenicity of the expressed antigens.
The bivalent bidirectional promoter expression cassette containing MARV and SEBOV antigens (MARV.mCMV.SEBOV) was extensively tested in rAd26 for genetic stability, expression levels of the two antigens (total and surface), and immunogenicity in mice against the encoded antigens. The overall design of rAd26 follows the rAd35 design where the expression cassette is places in the E1 region and each antigen is controlled by the centrally placed bidirectional mCMV promoter (
The total protein expression levels of the MARV and SEBOV antigens encoded in the rAd26.E1.MARV.mCMV.SEBOV were assessed by infecting A549 cells with 10000, 25000 and 50000 VP/cell, lysing the cells 48 hpi, and staining with anti-MARV or anti-SEBOV antibodies in a Western Blot (
Surface expression of the MARV and SEBOV antigens was assessed by infecting A549 cells with 100000, 20000, 4000 and 800 VP/cell, staining with anti-MARV or anti-SEBOV 48 hours after infection (48 hpi) and analyzing the MARV or SEBOV percent (%) positive cells by FACS (
The immunogenic potency of rAd26.E1.MARV.mCMV.SEBOV was evaluated by comparing the ability of the bivalent vector and a mixture of the single insert vectors to induce MARV and SEBOV specific T-cell and B-cell responses with ELISPOT and ELISA assays, respectively. For both assays, 12 mice per group were immunized intramuscularly (IM) with 1×109 VP of rAd26.E1.MARV-mCMV-SEBOV or with a mixture of 1×109 VP rAd26.E1.MARV and 1×109 VP rAd26.E1.SEBOV. To account for the possible adjuvating effect of the group receiving the total of 2×109 VP of single insert combination, 1×109 VP rAd26.empty vector was co-injected with the rAd26.E1.MARV-mCMV-SEBOV. As a negative control, two groups of five mice received a total of 2×109 VP rAd26.emtpy. Prior to vaccination, mice were also bled to generate naïve control serum (data not shown). The ELISPOT and ELISA assay results are shown as
The MARV and SEBOV specific T-cell responses, as measured in spot forming units/106 splenocytes (SFU/106) by ELISPOT, showed some differences between the double insert vector and the mixture of the single insert vectors, but the differences were only significant at the lower doses of 2×109 VP. In the group of mice immunized with the lower dose of the mixture, 2×109 VP rAd26.E1.SEBOV+rAd26.E1.MAR, there were significantly higher (p<0.01) MARV and (p<0.05) SEBOV specific T-cell responses as compared to the same dose of rAd26.E1.MARV.mCMV.SEBOV. These differences, however, were not observed for MARV or SEBOV specific T-cell responses in mice immunized with the higher 2×1010 VP dose of the vectors. Furthermore, the double insert vector provided potent T-cell responses for both antigens (
Based on the ELISA data there were also some differences in the B-cell response for the double insert vector compared to the mixture of the single insert vectors, but the differences were only seen with MARV. For SEBOV, there were no significant differences in the levels of SEBOV antibodies in mice immunized with either dose of the different vectors (
Thus, according to the data from FACS analysis for surface expression of the transgenes and the ELISPOT and ELISA assays to measure immunogenicity, the double insert vector rAd26.E1.MARV.mCMV.SEBOV was determined to provide potent expression and potent T-cell and B-cell immune responses against both the MARV and SEBOV antigens. There were some differences detected for the antigens with the double insert vector compared to the mixture of the single insert vectors, but rAd26.E1.MARV.mCMV.SEBOV provided high levels of surface expression of the two transgenes and induced potent T-cell and B-cell responses. Furthermore, based on PCR analysis and sequencing, rAd26.E1.MARV-mCMV-SEBOV was genetically stable. Therefore, it was determined that like rAd35 with a bidirectional mouse CMV promoter, rAd26 with a bidirectional mouse CMV promoter would be suitable for use in gene therapy and vaccine applications with regard to genetic stability, transgene expression, and immunogenicity of the expressed antigens.
As described supra, a large number of mCMV bidirectional promoter vectors, rAd35 and rAd26 containing different Filovirus glycoproteins as well as reporter genes (eGFP and Luciferase), were tested for genetic stability in PER.C6® cells, transgene protein expression (total and surface), and immunogenicity of the antigens with regard to both T-cell and B-cell responses. Considering the number of vectors tested, with five or more plaques tested for each vector, and the sensitivity of the E1 expression cassette PCR analysis for genetic stability, the rAd of the present invention with a bidirectional mCMV promoter were determined to be genetically stable with no deletion bands at p13. Furthermore, based on FACS analysis of transgene expression and ELISPOT and ELISA analysis of the immunogenicity of the expressed antigens with regard to T-cell and B-cell responses, the rAd of the present invention with a bidirectional promoter were determined to be suitable for use in gene therapy and vaccine applications. Thus, the rAd of the present invention with a mCMV bidirectional promoter provide a significant improvement compared to the bivalent rAd vectors previously described in the art.
| Number | Date | Country | Kind |
|---|---|---|---|
| 15163538 | Apr 2015 | EP | regional |
This application is a Section 371 of International Application No. PCT/EP2016/057982, which was published in the English Language on Oct. 20, 2016, under International Publication No. WO2016/166088, which claims priority to U.S. Provisional Application No. 62/147,453, filed on Apr. 14, 2015 and European Patent Application No. 15163538.0, filed on Apr. 14, 2015. Each disclosure is incorporated herein by reference in its entirety.
This invention was made with government support under Contract No. HHSN272200800056C by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2016/057982 | 4/12/2016 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2016/166088 | 10/20/2016 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5057540 | Kensil et al. | Oct 1991 | A |
| 5122458 | Post et al. | Jun 1992 | A |
| 5559099 | Wickham et al. | Sep 1996 | A |
| 5837511 | Falck-Pedersen et al. | Nov 1998 | A |
| 5837520 | Shabram et al. | Nov 1998 | A |
| 5846782 | Wickham et al. | Dec 1998 | A |
| 5851806 | Kovesdi et al. | Dec 1998 | A |
| 5891690 | Massie | Apr 1999 | A |
| 5965541 | Wickham et al. | Oct 1999 | A |
| 5981225 | Kochanek et al. | Nov 1999 | A |
| 5994106 | Kovesdi et al. | Nov 1999 | A |
| 5994128 | Fallaux et al. | Nov 1999 | A |
| 6020191 | Scaria et al. | Feb 2000 | A |
| 6040174 | Imler et al. | Mar 2000 | A |
| 6083716 | Wilson et al. | Jul 2000 | A |
| 6113913 | Brough et al. | Sep 2000 | A |
| 6225289 | Kovesdi et al. | May 2001 | B1 |
| 6261823 | Tang et al. | Jul 2001 | B1 |
| 6485958 | Blanche et al. | Nov 2002 | B2 |
| 7270811 | Bout et al. | Sep 2007 | B2 |
| 7326555 | Konz, Jr. et al. | Feb 2008 | B2 |
| 8932607 | Custers et al. | Jan 2015 | B2 |
| 20080032300 | Chatellard | Feb 2008 | A1 |
| Number | Date | Country |
|---|---|---|
| 853660 | Jul 1998 | EP |
| 1230354 | Aug 2002 | EP |
| 1601776 | Dec 2005 | EP |
| 2128261 | Dec 2009 | EP |
| 9003184 | Apr 1990 | WO |
| 9014837 | Dec 1990 | WO |
| 9611711 | Apr 1996 | WO |
| 9822588 | May 1998 | WO |
| 9839411 | Sep 1998 | WO |
| 9912568 | Mar 1999 | WO |
| 9941416 | Aug 1999 | WO |
| 199955132 | Nov 1999 | WO |
| 200029024 | May 2000 | WO |
| 200032754 | Jun 2000 | WO |
| 0029024 | Nov 2000 | WO |
| 2000070071 | Nov 2000 | WO |
| 0102607 | Jan 2001 | WO |
| 200166137 | Sep 2001 | WO |
| 0222080 | Mar 2002 | WO |
| 2002040665 | May 2002 | WO |
| 2003049763 | Jun 2003 | WO |
| 03061708 | Jul 2003 | WO |
| 03078592 | Sep 2003 | WO |
| 2003104467 | Dec 2003 | WO |
| 2004001032 | Dec 2003 | WO |
| 2004004762 | Jan 2004 | WO |
| 2004020971 | Mar 2004 | WO |
| 2004037294 | May 2004 | WO |
| 2004055187 | Jul 2004 | WO |
| 2005002620 | Jan 2005 | WO |
| 2005071093 | Aug 2005 | WO |
| 2005080556 | Sep 2005 | WO |
| 2006053871 | May 2006 | WO |
| 2006108707 | Oct 2006 | WO |
| 2006120034 | Nov 2006 | WO |
| 2007073513 | Jun 2007 | WO |
| 2007104792 | Sep 2007 | WO |
| 2007100908 | Sep 2007 | WO |
| 2007110409 | Oct 2007 | WO |
| 2009026183 | Feb 2009 | WO |
| 2009117134 | Sep 2009 | WO |
| 2010085984 | Aug 2010 | WO |
| 2010086189 | Aug 2010 | WO |
| 2010096561 | Aug 2010 | WO |
| 2011045378 | Apr 2011 | WO |
| 2011045381 | Apr 2011 | WO |
| 2013139911 | Sep 2013 | WO |
| 2013139916 | Sep 2013 | WO |
| Entry |
|---|
| Candolfi et al (Neuro-Oncology Jul. 2007, pp. 245-258). (Year: 2007). |
| Addison et al (J Gen Virol Jul. 1997 vol. 78, No. 7: pp. 1653-1661). (Year: 1997). |
| Int'l Search Report dated Jun. 20, 2016 in Int'l Application No. PCT/EP2016/057982. |
| Written Opinion dated Jun. 20, 2016 in Int'l Application No. PCT/EP2016/057982. |
| Chatellard et al, “The IE2 Promoter/Enhancer Region From Mouse CMV Provides High Levels of Therapeutic Protein Expression in Mammalian Cells,” Biotechnology and Bioengineering, vol. 96, No. 1, pp. 106-117 (2007). |
| Abrahamsen et al, “Construction of an Adenovirus Type 7a E1A-Vector,” Journal of Virology, vol. 71, No. 11, pp. 8916-8951 (1997). |
| Hsieh et al, “A Novel Targeting Modality to Enhance Adenoviral Replication by Vitamin D3 in Androgen-Independent Human Prostate Cancer Cells and Tumors,” Cancer Research, vol. 62, pp. 3084-3092 (2002). |
| Abbink et al, “Comparative Seroprevalance and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors From Subgroups B and D,” Journal of Virology, vol. 81, No. 9, pp. 4654-4663 (2007). |
| Amendola et al, “Coordinate Dual-Gene Transgenesis by Lentiviral Vectors Carrying Synthetic Bidirectional Promoters,” Nature Biotechnology, vol. 23, No. 1, pp. 108-116 (2005). |
| Bangari and Mittal, “Development of Nonhuman Adenoviruses As Vaccine Vectors,” Vaccine, vol. 24, No. 7, pp. 849-862 (2006). |
| Brough et al, “A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4,” Journal of Virology, vol. 70, No. 9, pp. 6497-6501 (1996). |
| De Felipe et al, “Inhibition of 2A-Mediated ‘Cleavage’ of Certain Artificial Polyproteins Bearing N-Terminal Signal Sequences,” Biotechnology Journal, vol. 5, pp. 213-223 (2010). |
| Belousova et al, “Circumventing Recombination Events Encountered With Production of a Clinical-Grade Adenoviral Vector With a Double-Expression Cassette,” Molecular Pharmacology, vol. 70, No. 5, pp. 1488-1493 (2006). |
| Cohen et al, “Chimpanzee Adenovirus CV-68 Adapted as a Gene Delivery Vector Interacts With the Coxsackievirus and Adenovirus Receptor,” Journal of General Virology, vol. 83, pp. 151-155 (2002). |
| Donnelly et al, “The ‘Cleavage’ Activities of Foot-And-Mouth Disease Virus 2A Site-Directed Mutants and Naturally Occurring ‘2A-Like’ Sequences,” Journal of General Virology, vol. 82, pp. 1027-1041 (2001). |
| Fallaux et al, “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication Competent Adenoviruses,” Human Gene Therapy, vol. 9, pp. 1909-1917 (1998). |
| Geisbert et al, “Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates Against Ebolavirus Challenge,” Journal of Virology, vol. 85, No. 9, pp. 4222-4233 (2011). |
| Havenga et al, “Novel Replication-Incompetent Adenoviral B-Group Vectors: High Vector Stability and Yield in PER. C6 Cells,” Journal of General Virology, vol. 87, pp. 2135-2143 (2006). |
| Farina et al, “Replication-Defective Vector Based on a Chimpanzee Adenovirus,” Journal of Virology, vol. 75, No. 23, pp. 11603-11613 (2001). |
| Goerke et al, “Development of a Novel Adenovirus Purification Process Utilizing Selective Precipitation of Cellular DNA,” Biotechnology and Bioengineering, vol. 91, pp. 12-21 (2005). |
| Hoganson et al, “Development of a Stable Adenoviral Vector Formulation,” Bioprocessing Journal, vol. 1, No. 1, pp. 43-48 (2002). |
| Gao et al, “A Cell Line for High-Yield Production of E1-Deleted Adenovirus Vectors Without the Emergence of Replication-Competent Virus,” Human Gene Therapy, vol. 11, pp. 213-219 (2000). |
| Harro et al, “Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B Gag Vaccines in Healthy Adults,” AIDS Research and Human Retroviruses, vol. 25, No. 1, pp. 103-114 (2009). |
| Holman et al, “Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Denque Virus Serotypes,” Clinical and Vaccine Immunology, vol. 14, No. 2, pp. 182-189 (2007). |
| Holterman et al, “Novel Replication-Incompetent Vector Derived From Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity With Ad5,” Journal of Virology, vol. 78, No. 23, pp. 13207-13215 (2004). |
| Lasaro et al, “New Insights on Adenovirus As Vaccine Vectors,” Molecular Therapy, vol. 17, No. 8, pp. 1333-1339 (2009). |
| Hu et al, “Comparative Immunogenicity of Recombinant Adenovirus-Vectored Vaccines Expressing Different Forms of Hemagglutinin (HA) Proteins From the H5 Serotype of Influenza A Viruses in Mice,” Virus Research, vol. 155, pp. 156-162 (2011). |
| Lemckert et al, “Generation of a Novel Replication-Incompetent Adenoviral Vector Derived From Human Adenovius Type 49: Manufacture on PER.C6 Cells, Tropism and Immunogenicity,” Journal of General Virology, vol. 87, pp. 2891-2899 (2006). |
| Kobinger et al, “Chimpanzee Adenovirus Vaccine Protects Against Zaire Ebola Virus,” Virology, vol. 346, Issue 2, pp. 394-401 (2006). |
| Mullick et al, “The Cumate Gene-Switch: A System for Regulated Expression in Mammalian Cells,” BMC Biotechnology, vol. 6, No. 43, pp. DOI: 10.1186/1472-6750-6-43 (2006). |
| Nan et al, “Development of an Ad7 Cosmid System and Generation of an Ad7DE1DE3HIVMN Env/Rev Recombinant Virus,” Gene Therapy, vol. 10, pp. 326-336 (2003). |
| Ophorst et al, “Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine Against Plasmodium Yoelii in Mice,” Infection and Immunity, vol. 74, No. 1, pp. 313-320 (2006). |
| Na et al, “Design of Ad5F35 Vectors for Coordinated Dual Gene Expression in Candidate Human Hematopoietic Stem Cells,” Experimental Hematology, vol. 38, pp. 446-452 (2010). |
| Ogun et al, “The Oligomerization Domain of C4-Binding Protein (C4bp) Acts as an Adjuvant, and the Fusion Protein Comprised of the 19-Kilodalton Merozoite Surface Protein 1 Fused With the Murine C4bp Domain Protects Mice From Malaria,” Infection and Immunity, vol. 76, No. 8, pp. 3817-3823 (2008). |
| Pham et al, “Concordant Activity of Transgene Expression Cassettes Inserted Into E1, E3, and E4 Cloning Sites in the Adenovirus Genome,” J. Gene Med., vol. 11, No. 3, pp. 197 doi:10.1002/jgm.1289 (2009). |
| Radosevic et al, “The Th1 Immune Response to Plasmodium Falciparum Circumsporozoite Protein is Boosted by Adenovirus Vectors 35 and 26 With a Homologous Insert,” Clinical and Vaccine Immunology, vol. 17, No. 11, pp. 1687-1694 (2010). |
| Small et al, “Construction and Characterization of E1- and E3-Deleted Adenovirus Vectors Expressing Two Antigens From Two Separate Expression Cassettes,” Human Gene Therapy, vol. 25, pp. 328-338 (2014). |
| Sullivan et al, “Accelerated Vaccination for Ebola Cirus Haemorrhagic Fever in Non-Human Primates,” Nature, vol. 424, pp. 681-684 (2003). |
| Schepp-Berglind et al, “Complex Adenovirus-Mediated Expression of West Niles Virus C, PreM, E, and NS1 Proteins Induces Both Humoral and Cellular Immune Response,” Clinical and Vaccine Immunology, vol. 14, No. 9, pp. 1117-1126 (2007). |
| Sullivan et al, “Immune Protection of Nonhuman Primates Against Ebola Virus With Single Low-Dose Adenovirus Vectors Encoding Modified GPs,” PLoS Medicine, vol. 3, Issue 6, pp. 865-873 (2006). |
| Szymczak et al, “Correction of Multi-Gene Dificiency In Vivo Using a Single ‘Self-Cleaving’ 2A Peptide-Based Retroviral Vector,” Nature Biotechnology, vol. 22, No. 5, pp. 589-594 (2004). |
| Tatsis et al, “A CD46-Binding Chimpanzee Adenovirus Vector as a Vaccine Carrier,” Molecular Therapy, vol. 15, No. 3, pp. 608-617 (2007). |
| Vogels et al, “Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity,” Journal of Virology, vol. 77, No. 15, pp. 8263-8271 (2003). |
| Zhou et al, “A Chimpanzee-Origin Adenovirus Vector Expressing the Rabies Virus Glycoprotein as an Oral Vaccine Against Inhalation Infection With Rabies Virus,” Molecular Therapy, vol. 14, No. 5, pp. 662-672 (2006). |
| Vemula and Mittal, “Production of Adenovirus Vectors and Their Use As a Delivery System for Influenza Vaccines,” Expert Opin. Biol. Ther., vol. 10, No. 10, pp. 1469-1487 (2010). |
| Vogels et al, “High-Level Expression From Two Independent Expression Cassettes in Replication-Incompetent Adenovirus Type 35 Vector,” Journal of General Virology, vol. 88, pp. 2915-2924 (2007). |
| Zhou et al, “A Universal Influenza A Vaccine Based on Adenovirus Expressing Matrix-2 Ectodomain and Nucleoprotein Protects Mice From Lethal Challenge,” Molecular Therapy, vol. 18, No. 12, pp. 2182-2189 (2010). |
| Ebert et al., “Tetracycline-Regulated Adenovirus Encoding Dominant-Negative Caspase-9 is Regulated in Rat Brain and Protects Against Neurotoxin-Induced Cell Death in Vitro, but Not in Vivo”, Experimental Neurology, vol. 191, No. 1, pp. S80-S94 (Feb. 2005). |
| Number | Date | Country | |
|---|---|---|---|
| 20180135075 A1 | May 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62147453 | Apr 2015 | US |
